BCL2L1 and glioblastoma: Specifically, SF3B1-blockade downregulated anti-apoptotic Bcl-xL, while upregulated the pro-apoptotic Bcl-xS, in GBM, both in vitro and in vivo, but not in non-tumor brain cell cultures.